Interpace Biosciences prelim Q3 2026 revenue $10.1M-$10.4M, up ~15-18% YoY

INTERPACE BIOSCIENCES, INC.

Preliminary unaudited Q3 2026 revenue expected to range $10.1 million to $10.4 million.
Expected ~11%-14% quarter-over-quarter growth from $9.1 million in Q2 2026 and ~15%-18% year-over-year growth from $8.8 million in Q3 2025.
Results are preliminary and subject to quarter-end closing procedures and review by the company's independent registered public accounting firm.
Press release furnished as Exhibit 99.1; full Q3 2026 financial results expected to be reported at a later date.
Release references a free writing prospectus related to an offering with a registration statement filed with the SEC.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.